Relationship between oxidized low-density lipoprotein antibodies and obesity in different glycemic situations

Diabetes, Metabolic Syndrome and Obesity

Volumn 7, Issue , 2014, Pages 513-520

  Babakr, Abdullatif Taha ^a   Elsheikh, Osman Mohamed ^b   Almarzouki, Abdullah A ^a   Assiri, Adel Mohamed ^a   Abdalla, Badr Eldin Elsonni ^c   Zaki, Hani Yousif ^d   Fatani, Samir H ^a   NourEldin, EssamEldin Mohamed ^a  

^a UMM AL QURA UNIVERSITY   (Saudi Arabia)

^b International University of Africa   (Sudan)

^c KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF GEZIRA   (Sudan)

Author keywords

Anti oxidized low density lipoprotein antibodies; Body mass index; Diabetes; Impaired glucose tolerance; Obesity

Indexed keywords

OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

EID: 84908276986     PISSN: None     EISSN: 11787007     Source Type: Journal    
DOI: 10.2147/DMSO.S70904     Document Type: Article

References (33)

1. Zuliani G, Morieri ML, Volpato S, et al. Determinants and clinical significance of plasma oxidized LDLs in older individuals. A 9 years follow-up study. Atherosclerosis. 2013;226(1):201–207.
2. Virella G, Lopes-Virella MF. The pathogenic role of the adaptive immune response to modified LDL in diabetes. Front Endocrinol (Lausanne). 2012;3:76.
3. Perrin-Cocon L, Diaz O, Andre P, Lotteau V. Modified lipoproteins provide lipids that modulate dendritic cell immune function. Biochimie. 2013;95(1):103–108.
4. Kaplan M, Aviram M, Hayek T. Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: role of insulin therapy. Pharmacol Ther. 2012;136(2):175–185.
5. El-Bassiouni EA, Helmy MH, El-Zoghby SM, El-Nabi Kamel MA, Hosny RM. Relationship between level of circulating modified LDL and the extent of coronary artery disease in type 2 diabetic patients. Br J Biomed Sci. 2007;64(3):109–116.
6. Yang H, Mohamed AS, Zhou SH. Oxidized low density lipoprotein, stem cells, and atherosclerosis. Lipids Health Dis. 2012;11:85.
7. Wegner M, Piorunska-Stolzmann M, Araszkiewicz A, et al. Does oxidized LDL contribute to atherosclerotic plaque formation and microvascular complications in patients with type 1 diabetes? Clin Biochem. 2012;45(18):1620–1623.
8. Shimada K, Mokuno H, Matsunaga E, et al. Predictive value of circulating oxidized LDL for cardiac events in type 2 diabetic patients with coronary artery disease. Diabetes Care. 2004;27(3):843–844.
9. Garrido-Sanchez L, Cardona F, Garcia-Fuentes E, et al. Anti-oxidized low-density lipoprotein antibody levels are associated with the development of type 2 diabetes mellitus. Eur J Clin Invest. 2008;38(9):615–621.
10. Jiang X, Yang Z, Chandrakala AN, Pressley D, Parthasarathy S. Oxidized low density lipoproteins – do we know enough about them? Cardiovasc Drugs Ther. 2011;25(5):367–377.
11. Parthasarathy S, Raghavamenon A, Garelnabi MO, Santanam N. Oxidized low-density lipoprotein. Methods Mol Biol. 2010;610:403–417.
12. Lopes-Virella MF, Virella G. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb. 2013;20(10):743–754.
13. Virella G, Carter RE, Saad A, Crosswell EG, Game BA, Lopes-Virella MF. Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol. 2008;127(3):394–400.
14. Lopes-Virella MF, Virella G. Clinical significance of the humoral immune response to modified LDL. Clin Immunol. 2010;134(1):55–65.
15. Hunt KJ, Baker N, Cleary P, et al. Oxidized LDL and AGE-LDL in circulating immune complexes strongly predict progression of carotid artery IMT in type 1 diabetes. Atherosclerosis. 2013;231(2):315–322.
16. Crisby M, Henareh L, Agewall S. Relationship between oxidized LDL, IgM, and IgG Autoantibodies to oxLDL levels with recurrent cardiovascular events in Swedish patients with previous myocardial infarction. Angiology. November 27, 2013. [Epub ahead of print.]
17. Lopes-Virella MF, Baker NL, Hunt KJ, Lachin J, Nathan D, Virella G. Oxidized LDL immune complexes and coronary artery calcification in type 1 diabetes. Atherosclerosis. 2011;214(2):462–467.
18. Santos AO, Fonseca FA, Fischer SM, et al. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. Clin Chim Acta. 2009;406(1–2):113–118.
19. Garrido-Sanchez L, Garcia-Pinilla JM, Jimenez-Navarro M, et al. Reduced levels of anti-MDA LDL antibodies in patients with carbohydrate metabolism disorders. Clin Lab. 2011;57(11–12):901–907.
20. Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation. 2004;110(17):2552–2558.
21. Rathmann W, Giani G. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(10):2568–2569.
22. Du M, Wu M, Fu D, et al. Effects of modified LDL and HDL on retinal pigment epithelial cells: a role in diabetic retinopathy? Diabetologia. 2013;56(10):2318–2328.
23. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26(3):917–932.
24. Rajkovic N, Zamaklar M, Lalic K, et al. OP3: oxidized LDL as residual lipid risk marker in type 2 diabetes. Diabetes Metab. 2012;38(Suppl 5): S98–S99.
25. Cicero AF, Reggi A, Tartagni E, Grandi E, D’Addato S, Borghi C; Brisighella Heart Study. Dietary determinants of oxidized-low-density lipoprotein antibodies in a sample of pharmacologically untreated non-smoker subjects: data from the Brisighella Heart Study. Adv Clin Exp Med. 2013;22(1):69–76.
26. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26(11):3160–3167.
27. Holvoet P, Macy E, Landeloos M, et al. Analytical performance and diagnostic accuracy of immunometric assays for the measurement of circulating oxidized LDL. Clin Chem. 2006;52(4):760–764.
28. Craig WY, Poulin SE, Nelson CP, Ritchie RF. ELISA of IgG antibody to oxidized low-density lipoprotein: effects of blocking buffer and method of data expression. Clin Chem. 1994;40(6):882–888.
29. Matsumoto H, Uchino M, Kato M. Evaluation of haemoglobin A1c measurement by an enzymatic method using an automated analyser that has an on-board haemolysis system. Ann Clin Biochem. 2013;50 Pt 5:443–449.
30. Luca AC, Iordache C. Obesity – a risk factor for cardiovascular diseases. Rev Med Chir Soc Med Nat Iasi. 2013;117(1):65–71.
31. Beck J, Ferrucci L, Sun K, et al. Circulating oxidized low-density lipoproteins are associated with overweight, obesity, and low serum carotenoids in older community-dwelling women. Nutrition. 2008;24(10):964–968.
32. Tumova E, Sun W, Jones PH, Vrablik M, Ballantyne CM, Hoogeveen RC. The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013;2013:729515.
33. Sanches LB, da Silva IT, Paz AF, et al. Anti-oxLDL autoantibodies and their correlation with lipid profile and nutritional status in adolescents. J Pediatr (Rio J). 2008;84(3):258–263.